Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yo-Kyung Chung"'
Autor:
Se Jin Im, Sang In Yang, Se Hwan Yang, Dong Hoon Choi, So Young Choi, Hea Sook Kim, Do Soo Jang, Kyeong Sik Jin, Yo-Kyung Chung, Seung-Hee Kim, Sang Hoon Paik, Yoo Chang Park, Moon Koo Chung, Yong Bum Kim, Kang-Hyun Han, Kwan Yong Choi, Young Chul Sung
Publikováno v:
PLoS ONE, Vol 6, Iss 9, p e24574 (2011)
Human IgG1 Fc has been widely used as a bioconjugate, but exhibits shortcomings, such as antibody- and complement-mediated cytotoxicity as well as decreased bioactivity, when applied to agonistic proteins. Here, we constructed a nonimmunogenic, noncy
Externí odkaz:
https://doaj.org/article/5a9c73e6d3dc46749be05e8572f27352
Autor:
Yo-Kyung Chung, Chihwa Kim, Eui-cheol Jo, Jinwook Seo, Jongmun Sohn, Byoung-Ju Lee, Hyi-Jeong Ji, Jaehyeon Lee
Publikováno v:
Journal of Human Genetics
Hunter syndrome is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to the accumulation of glycosaminoglycans (GAGs). Two recombinant enzymes, idursulfase and idursulfase beta are current
Autor:
Dong-Kyu Jin, Young Bae Sohn, Yeon Joo Yook, Jieun Lee, Yo Kyung Chung, Jong Mun Sohn, Younghee Kwun, Chi Hwa Kim, Ah-Ra Ko, Mi Sun Chang, Jin Young Lee
Publikováno v:
Glycoconjugate journal. 31(4)
Mucopolysaccharidosis II (MPS II, Hunter syndrome; OMIM 309900) is an X-linked lysosomal storage disease caused by a deficiency in the enzyme iduronate-2-sulfatase (IDS), leading to accumulation of glycosaminoglycans (GAGs). For enzyme replacement th
Publikováno v:
Archives of pharmacal research. 35(5)
The Fc fusion technology has been introduced to generate long-acting antagonistic drugs such as Enbrel, Orencia and Amevive. Here, Genexine created a novel noncytolytic hybrid Fc (hyFc) as a carrier of agonistic protein drugs using naturally existing
Autor:
Yo-Kyung Chung, Ho-Jin Heo, Eun-Ki Kim, Hye-Kyung Kim, Tae-Lin Huh, Yoongho Lim, Sung-Koo Kim, Dong-Hoon Shin
Publikováno v:
Molecules & Cells (Elsevier B.V); 2001, Vol. 11 Issue 2, p137-143, 7p, 2 Charts, 6 Graphs